Literature DB >> 3930575

Application of a timing protocol to the reduction of inter-plate variability in the indirect enzyme immunoassay for detection of anti-Brucella antibody.

P F Wright, W A Kelly, D E Gall.   

Abstract

A simple timing protocol was developed to monitor chromogen conversion in an enzyme immunoassay, performed in microtiter plates, for the detection of antibody to Brucella abortus in bovine serum. Application of this protocol decreased the inter-plate coefficient of variation from 28.6% to 6.8% when optical density (OD) values, subsequent to the reaction of a standard antibody reagent, were compared to a static development time. Substantial reductions in variation were also observed for low titered seropositive and for seronegative control reagents. The timing protocol was based on the mathematical relationship of the OD value at 4 minutes of development to a predetermined target OD value (1.0) for a standard antibody reagent. Application of this relationship to the calculation of a variable, final development time eliminated the need for extensive data manipulation and assay calibration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930575     DOI: 10.1080/01971528508063029

Source DB:  PubMed          Journal:  J Immunoassay        ISSN: 0197-1522


  11 in total

1.  Optimization and standardization of an enzyme-linked immunosorbent assay protocol for serodiagnosis of Actinobacillus pleuropneumoniae serotype 5.

Authors:  Y L Trottier; P F Wright; S Larivière
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

2.  A method for preparation of IgA from bovine mammary secretions.

Authors:  K Nielsen
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

3.  Bovine monoclonal antibody specific for Brucella abortus lipopolysaccharide.

Authors:  K H Nielsen; M D Henning
Journal:  Vet Immunol Immunopathol       Date:  1989-07       Impact factor: 2.046

4.  Competitive and indirect enzyme-linked immunosorbent assays for Mycobacterium bovis infections based on MPB70 and lipoarabinomannan antigens.

Authors:  E A Sugden; K Stilwell; E B Rohonczy; P Martineau
Journal:  Can J Vet Res       Date:  1997-01       Impact factor: 1.310

5.  Seroepidemiology of strongyloidiasis in the Peruvian Amazon.

Authors:  Pablo P Yori; Margaret Kosek; Robert H Gilman; Julianna Cordova; Caryn Bern; Cesar Banda Chavez; Maribel Paredes Olortegui; Carmen Montalvan; Graciela Meza Sanchez; Bevelle Worthen; James Worthen; Fay Leung; Carlos Vidal Oré
Journal:  Am J Trop Med Hyg       Date:  2006-01       Impact factor: 2.345

6.  The use of divalent cation chelating agents (EDTA/EGTA) to reduce non-specific serum protein interaction in enzyme immunoassay.

Authors:  K Nielsen; L Kelly; D Gall; P Smith; J Bosse; P Nicoletti; W Kelly
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

7.  Development of a competitive enzyme-linked immunosorbent assay for detection of bovine, ovine, porcine, and equine antibodies to vesicular stomatitis virus.

Authors:  A Afshar; N H Shakarchi; G C Dulac
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

8.  Chromatographic purification and characterization of antigens A and D from Mycobacterium paratuberculosis and their use in enzyme-linked immunosorbent assays for diagnosis of paratuberculosis in sheep.

Authors:  E A Sugden; B W Brooks; N M Young; D C Watson; K H Nielsen; A H Corner; C Turcotte; A Michaelides; R B Stewart
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

9.  Brucella abortus 1119-3 O-chain polysaccharide to differentiate sera from B. abortus S-19-vaccinated and field-strain-infected cattle by agar gel immunodiffusion.

Authors:  J W Cherwonogrodzky; K H Nielsen
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

Review 10.  A review of enzyme immunoassay for detection of antibody to Brucella abortus in cattle.

Authors:  K H Nielsen; P F Wright; W A Kelly; J H Cherwonogrodzky
Journal:  Vet Immunol Immunopathol       Date:  1988-06       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.